INS and type 2 diabetes mellitus: The addition of insulin sensitizers (metformin and pioglitazone) or sitagliptin to short‐term intensive insulin therapy (SIIT) facilitated SIIT implementation and enhanced short‐term glycemic control in patients with newly diagnosed type 2 diabetes.